Outline

- How to measure success
- Examples of successful HTA studies
- Concluding comments
How I define success

• Partnerships/collaborations
• Grants and contracts
• Publications
• Press coverage
• Revenue/Profits
• Practice or policy changes
• Others?
Examples


Epilepsy

- A common neurological disorder (incidence~ 0.05% per year)

Treatment

- Older anti-epileptics
  - Carbamazepine (CBZ), phenytoin (PHT) – fairly inexpensive (cost several hundred dollars per year) and generally effective
  - Valproate (VPA) – similar effectiveness but more expensive (2x)

- Newer Anti-epileptics
  - Topiramate (TPM), Levetiracetam (LEV), lamotrigine (LTG), and others – at least as effective and much more expensive (up to 100x)

- CBZ and PHT may cause potentially life-threatening side effects SJS and TEN
Cost-effectiveness of HLA-B*1502 testing for newly diagnosed epilepsy patients

- HLA-B*1502 has been identified as the genetic risk factor for SJS/TEN (Odds Ratio=1,357) and is common among some Asian groups.
- This finding raises the question of whether to genotype for HLA-B*1502 in Singapore prior to prescribing CBZ.
- With a Duke-NUS PhD student and collaborators from HSA, we conducted a cost-effectiveness analysis to evaluate the benefits and costs testing for newly diagnosed epilepsy patients.

Research Question: Should HLA-B*1502 testing be used routinely in clinical care for newly diagnosed epilepsy patients?
Cost-effectiveness of HLA-B*1502 testing for newly diagnosed epilepsy patients

**Pros**
- Reduce mortality and morbidity resulting from SJS/TEN
- Avoid high medical cost for SJS/TEN treatment

**Cons**
- Genotyping costs $ (SGD205)
- Expensive alternative drug (>2x cost of CBZ) elevates long-term treatment cost
- Low population HLA-B*1502 frequency (14.87%) and low PPV(5.96%) suggests payoff is low
• We found HLA-B*1502 testing to be highly cost-effective for Singapore Chinese and Malay patients (but not Indians) based on established guidelines for cost effectiveness.
Impact

• In April 2013, MOH made an announcement that HLA-B*1502 genotyping prior to the initiation of carbamazepine therapy in new patients of Asian ancestry would be the new standard of care.

• HSA, together with MOH, issued a Dear Healthcare Professional Letter to communicate the new recommendations.

• 75% of the test cost subsidized for low-income patients

• Several hospitals now offer the test with a turnover time of 2-4 working days

Genotyping can help avoid SJS/TEN in epileptic patients

Asian patients with a particular genetic trait have a higher risk of developing Steven-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with the antiepileptic drugs carbamazepine and phenytoin. But genotyping for human leukocyte antigen variant (HLA)-B*1502 allele and providing more expensive alternate antiepileptic drugs to those who test positive is cost-effective for Singaporean Chinese and Malays, but not for Singaporean Indians, a local research has revealed. The researchers used patient data to develop a statistical model that took into account costs of epilepsy treatments and genotyping, reductions in quality of life and increased costs resulting from SJS/TEN complications, the prevalence of the risk allele, the positive predictive value (PPV) of genotyping, life expectancy, and other factors. [Neurology 2012;79:1259-1267]

The options were treatment with carbamazepine or phenytoin without genotyping or providing more expensive drugs that do not induce SJS/TEN to all patients without genotyping.

Lack of cost-effectiveness is no reason to not offer targeted therapy to low-risk Singaporean Indians

Compared with no genotyping and providing carbamazepine to all, genotyping at the cost of $205 per patient results in an incremental cost-effectiveness ratio of $38,620/QALY for Chinese patients, $8,420/QALY for Malays, and $122,530/QALY for Indians in Singapore, said researchers Ms. Dong Di of the Duke-NUS Graduate Medical School, Singapore. Lower amount denotes higher cost-effectiveness.

With an odds ratio of 1.367, PPV of 5.6 percent and negative predictive value of 99.9 percent, the HLA-B*1502 testing can have applications for the Han Chinese, Malaysians and South Indians in other countries. The allele is absent among US Caucasians, Hispanics, native Americans and Africans, but has 5 percent to 27 percent prevalence in the Han Chinese, Malays, Thais, Filipinos and Vietnamese.

However, the absence of this allele in other groups does not mean they cannot develop SJS/TEN, cautioned Associate Professor Eric A. Finkelstein, deputy director of the Health Services & Systems Research Program at Duke-NUS.

Also, lack of cost-effectiveness is no reason to not offer targeted therapy to low-risk Singaporean Indians who could potentially pay for higher treatment costs to avoid SJS/TEN altogether, said Finkelstein.
Results of samples genotyped for HLA-B*1502

As of 31 Dec 2015, 2,244 samples have been genotyped, of which **11.2% tested positive** for HLA-B*1502
No SJS adverse event related to carbamazepine have been reported since the letter was issued!
Cost-effectiveness of HLA-B*5801 testing for chronic gout patients

• **Gout is the most common inflammatory arthritis among men.**
  - Prevalence: 2.6% - 8% (Lawrence, 2008)
  - Deposition of uric acid crystals
  - Severe pain, joint damage, and loss of physical function

• **Allopurinol is the first-line urate lowering therapy (ULT) for chronic gout management.**
  - Effective and relatively inexpensive
  - Can also cause SJS/TEN
Cost-effectiveness of HLA-B*5801 testing for chronic gout patients

- Though genetic association between HLA-B*5801 allele and allopurinol-induced SJS has been demonstrated, the predictive power of HLA-B*5801 test in Singapore population is low, and the alternative gout treatments may be inferior in efficacy and are more costly.
- With a Duke-NUS PhD student and collaborators from HSA, NUH, and NUS, we conducted a cost-effectiveness analysis to evaluate the benefit and cost of applying HLA-B*5801 testing and/or a safety monitoring program among gout patients initiating allopurinol.

Research Question: Should HLA-B*5801 testing and/or safety monitoring be used routinely in clinical care for newly diagnosed gout patients?
Alternative to genetic testing?

• Safety monitoring

• Early withdrawal of allopurinol
  – better prognosis
  – lower mortality of SJS/TEN
    odds ratio= 0.69 for each day of early withdrawal (Garcia-Doval, 2000)
  – No structured safety program documented
AIM: Compare the cost-effectiveness of 6 strategies of chronic gout management from the Singapore health system perspective

1. ULT
   Standard ULT using allopurinol as first line drug

2. ULT + SP
   Standard ULT + hypothetical safety program

3. G → ULT
   Genetic test-guided ULT

4. G → SP
   Genetic test + safety program for test positive individuals

5. G → ULT → SP
   Allopurinol as 2nd line in the presence of SP

6. No ULT
   Only manage acute flares

ULT: urate lowering therapy
SP: safety program
G: HLA-B*5801 genetic testing
1. **Allopurinol treatment, without genetic testing**, despite the risk of inducing life-threatening SJS/TEN, is the preferred strategy for Singapore from C/E perspective.

2. **Genetic test-guided drug selection** is not preferred from cost-effectiveness perspective.

   - Compared to allopurinol, it has higher cost, but paradoxically gives lower QALYs.
   - Alternatives to allopurinol are limited. If avoiding allopurinol, some test positive patients will receive no urate lowering therapy, and have poor gout management in the long term.
   - At the **population level**, the long term risks of forgoing allopurinol treatment (in 18.5% of population) is higher than the benefits from preventing SJS (in 0.2% of population).
3. **Allopurinol+ Safety program can be cost-effective compared with standard allopurinol if:**
   - Safety program can reduce SJS/TEN *mortality* by 47%, or
   - **Cost** of safety program drops below $40, or
   - In high risk groups of patients (where the incidence of allopurinol-induced SJS/TEN is higher than 0.32%)

4. **Allopurinol as 2nd line for test positive patients who fail probenecid, in the presence of safety program**
   - Currently not cost-effective
   - Will be cost-effective when testing costs less than $90.
Impact

• The Health Science Authority (HSA) has plans to issue a Dear Health Care Professional Letter (DHCPL) to provide advice regarding genotyping prior to use of allopurinol in Singapore.

• **Despite lack of cost-effectiveness**, HSA identified a lab that will do HLA-B*580 testing, in part, because we show (in another study) that some people are willing to pay a high price for piece of mind
  – It’s not all about CEA

---

Research Article
For reprint orders, please contact: reprints@futuremedicine.com

Cost–effectiveness analysis of genotyping for *HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore
Comparing the two studies

• Treatments guided by genetic testing that can predict ADRs are not always cost-effective, even though ADR risk is reduced.

• Testing is unlikely to be cost-effective when:
  - Positive predictive power is low
  - Alternative drugs are limited
  - Alternative drugs are inferior in efficacy, or very expensive

• In general this is my take-away for precision medicines
  - Sometimes cost effective, sometimes not
Prevalence of GDM in Singapore has increased due to higher rates of obesity and advancing maternal age

GDM is associated with higher rates of maternal and fetal morbidity.

Singapore does not routinely screen for GDM

In collaboration with and a third year Duke-NUS medical student, KK Hospital and members of the Gusto (birth cohort) study team we conducted a cost-effectiveness analysis of gestational diabetes screening strategies in Singapore.

Research Question: Is it cost-effective to universally screen all pregnant women for GDM?
We show DGM screening to be highly cost effective

Practice change: KKH Women’s and Children’s hospital & Singapore General Hospital will be offering GDM screening to all pregnant patients at 24 to 28 weeks gestation as a pilot.

Impact

Diabetes screening for expectant mums

KKH, SGH to offer service for gestational diabetes from Jan as part of a 6-month trial

From January next year, all expectant mothers at KK Women’s and Children’s Hospital (KKH) and Singapore General Hospital will be offered screenings for gestational diabetes – a temporary condition that occurs during pregnancy.

On average, KKH sees around 12,000 births in a year.

As part of a six-month trial, the screenings will be offered to women at 24 to 28 weeks of pregnancy, when symptoms tend to appear.

KKH currently offers screenings mainly to pregnant women identified as high-risk. They include those with a high body mass index, first-degree relatives with diabetes, or those aged 35 and above.

But according to a study published by KKH and the Duke-NUS Graduate Medical School last month, the current approach of targeted screening fails to identify more than 80% of mothers with mild diabetes.

The new trial aims to enable earlier detection and intervention.

Around one in 10 pregnant women develops gestational diabetes, said Professor Tan Kok Hian, head of perinatal audit and epidemiology unit at KKH.

This is based on data from a cohort of some 924 pregnant women who took part in the long-term study, Growing Up in Singapore Towards Healthy Outcomes. All of them were tested – not just the women identified as “high-risk”.

They are screened using an oral glucose tolerance test, where two blood samples are taken, one before consuming a flavoured sweet drink, and another two hours after the drink. Both samples are tested to determine the level of glucose in the patient’s blood.

The test costs about $20 for patients with subsidies, and about $40 for those without.

Mothers diagnosed with gestational diabetes go through counselling to help them monitor and manage their condition. This may be done through dietary control or prescription of insulin.

“Medical intervention for patients with gestational diabetes reduces complication rates by as much as 40 per cent,” said Prof Tan.

Gestational diabetes can lead to health risks.

Babies have a higher chance of weighing more than 4kg at birth, and mothers may suffer obstructed labour.

During pregnancy, mothers may develop high blood pressure or go into pre-term labour, when symptoms of labour occur before 37 weeks of pregnancy.

This could lead to premature birth.

Mothers also have a higher chance of developing Type 2 diabetes after giving birth.

Corporative communications manager Lillian Lee has often been underweight, so it came as a surprise when she was diagnosed with gestational diabetes.

“I had to control my diet, otherwise my baby could have grown quite big,” said the 40-year-old, who was first screened for the condition in 2012.

byseow@sph.com.sg
Concluding Comments

- There is much potential for high quality HTA studies to help guide decision making in health care
  - Irrespective of an HTA regulatory authority
- CEA studies may be part of a successful HTA strategy.
  - But may not be!
- Other types of evidence may be more compelling
  - Need to know your stakeholder
QUESTIONS?